PL445129A1 - Peptydowe pochodne 1-(3-hydroksypropylo)-1H-pirolo-2,5-dionu, zastosowanie medyczne tych związków oraz sposób ich otrzymywania - Google Patents

Peptydowe pochodne 1-(3-hydroksypropylo)-1H-pirolo-2,5-dionu, zastosowanie medyczne tych związków oraz sposób ich otrzymywania

Info

Publication number
PL445129A1
PL445129A1 PL445129A PL44512923A PL445129A1 PL 445129 A1 PL445129 A1 PL 445129A1 PL 445129 A PL445129 A PL 445129A PL 44512923 A PL44512923 A PL 44512923A PL 445129 A1 PL445129 A1 PL 445129A1
Authority
PL
Poland
Prior art keywords
dione
pyrrole
hydroxypropyl
compounds
subject
Prior art date
Application number
PL445129A
Other languages
English (en)
Other versions
PL249308B1 (pl
Inventor
Janusz RACHOŃ
Mateusz Daśko
Karol Biernacki
Olga Ciupak
Sebastian DEMKOWICZ
Original Assignee
Politechnika Gdańska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Politechnika Gdańska filed Critical Politechnika Gdańska
Priority to PL445129A priority Critical patent/PL249308B1/pl
Publication of PL445129A1 publication Critical patent/PL445129A1/pl
Publication of PL249308B1 publication Critical patent/PL249308B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Przedmiotem wynalazku są związki chemiczne, będące akceptorami Michaela, charakteryzujące się strukturą chemiczną umożliwiającą ich wysoką reaktywność w reakcjach addycji Michaela, czyli addycji nukleofilowej do α,β-nienasyconych związków karbonylowych czy acylowych. Przedmiotem wynalazku jest pierwsze zastosowanie medyczne peptydowych pochodnych 1-(3-hydroksypropylo)-1H-pirolo-2,5-dionu. Przedmiotem wynalazku jest medyczne zastosowanie peptydowych pochodnych 1-(3-hydroksypropylo)-1H-pirolo-2,5-dionu jako leków, w tym zwłaszcza jako leków przeciwwirusowych o właściwościach inhibitora proteaz cysteinowych, w tym proteazy SARS CoV-2 Mpro oraz innych inhibitorów proteaz cysteinowych. Wynalazek dotyczy również zastosowania tych związków do wykorzystania in vitro np. w diagnostyce jako inhibitorów proteazy cysteinowej, w tym proteazy SARS CoV2 Mpro oraz innych inhibitorów proteaz cysteinowych. W szczególności przedmiotowe związki - peptydowe pochodne 1-(3-hydroksypropylo)-1H-pirolo-2,5-dionu znajdują zastosowanie medyczne jako leki w terapii przeciwwirusowej, a w szczególności w leczeniu infekcji wirusowych wywołanych koronawirusem SARS CoV-2, w tym COVID19 oraz innych koronawirusów odpowiedzialnych za ciężki ostry zespół oddechowy (SARS), zwłaszcza ssaków, w tym ludzi. Przedmiotem wynalazku jest ponadto sposób otrzymywania tych nowych związków na bazie peptydowych pochodnych 1-(3-hydroksypropylo)-1H-pirolo-2,5-dionu.
PL445129A 2023-06-06 2023-06-06 Peptydowe pochodne 1-(3-hydroksypropylo)-1H-pirolo-2,5-dionu, zastosowanie medyczne tych związków oraz sposób ich otrzymywania PL249308B1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL445129A PL249308B1 (pl) 2023-06-06 2023-06-06 Peptydowe pochodne 1-(3-hydroksypropylo)-1H-pirolo-2,5-dionu, zastosowanie medyczne tych związków oraz sposób ich otrzymywania

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL445129A PL249308B1 (pl) 2023-06-06 2023-06-06 Peptydowe pochodne 1-(3-hydroksypropylo)-1H-pirolo-2,5-dionu, zastosowanie medyczne tych związków oraz sposób ich otrzymywania

Publications (2)

Publication Number Publication Date
PL445129A1 true PL445129A1 (pl) 2024-12-09
PL249308B1 PL249308B1 (pl) 2026-03-23

Family

ID=93799861

Family Applications (1)

Application Number Title Priority Date Filing Date
PL445129A PL249308B1 (pl) 2023-06-06 2023-06-06 Peptydowe pochodne 1-(3-hydroksypropylo)-1H-pirolo-2,5-dionu, zastosowanie medyczne tych związków oraz sposób ich otrzymywania

Country Status (1)

Country Link
PL (1) PL249308B1 (pl)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432301A (zh) * 2020-11-03 2022-05-06 北京大学 一种共价抑制剂衍生物及其在治疗病毒感染方面的应用
WO2023283256A1 (en) * 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432301A (zh) * 2020-11-03 2022-05-06 北京大学 一种共价抑制剂衍生物及其在治疗病毒感染方面的应用
WO2023283256A1 (en) * 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IO ANTONOPOULOU, ELEFTHERIA SAPOUNTZAKI, ULRIKA ROVA, PAUL CHRISTAKOPOULOS: "Computational and Structural Biotechnology Journal, 2022, 20, 1306–1344", INHIBITION OF THE MAIN PROTEASE OF SARS-COV-2 (MPRO) BY REPURPOSING/DESIGNING DRUG-LIKE SUBSTANCES AND UTILIZING NATURE’S TOOLBOX OF BIOACTIVE COMPOUNDS *

Also Published As

Publication number Publication date
PL249308B1 (pl) 2026-03-23

Similar Documents

Publication Publication Date Title
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
EA202191801A1 (ru) Гетероциклические ингибиторы mat2a и способы применения для лечения рака
MX2025011950A (es) Inhibidores macrociclicos de ras
MX2022000711A (es) Inhibidores de parp1.
EA202191800A1 (ru) Азагетеробициклические ингибиторы мат2а и способы их применения для нацеливания на рак
BR112021023825A2 (pt) Inibidores heterobicíclicos de mat2a e métodos de uso para tratamento de câncer
BR112023020219A2 (pt) Anticorpos anti-il-2r agonistas e métodos de uso
BR112022007867A2 (pt) Degradadores de pequena molécula de helios e métodos de uso
MY154869A (en) Composition for treating metabolic syndrome
CL2008002207A1 (es) Composicion farmaceutica que comprende inmunosupresores para la mejora del efecto en el uso de un antagonista de interleucina-6 (il-6) para el tratamiento de enfermedades relacionadas con il-6 (div. sol. 896-04).
BRPI0612309B8 (pt) compostos e composições farmacêuticas antivirais
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
MX2022013081A (es) Compuestos para el tratamiento de sars.
EA200700168A1 (ru) Производные замещенной циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы
BRPI0316532B8 (pt) composições farmacêuticas compreendendo uma droga básica ou ácida, um tensoativo, e um ácido ou base solúvel em água fisiologicamente tolerável
DE60212949D1 (de) Antivirale pyrazolopyridin verbindungen
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
MX2022014303A (es) Compuestos para el tratamiento del sars.
CO2023012342A2 (es) Inhibidores de enzimas
GEAP202516674A (en) Indazole macrocycles and their use
PL445129A1 (pl) Peptydowe pochodne 1-(3-hydroksypropylo)-1H-pirolo-2,5-dionu, zastosowanie medyczne tych związków oraz sposób ich otrzymywania
PL445128A1 (pl) Peptydowe pochodne 1-(2-hydroksyetylo)-1H-pirolo-2,5-dionu, zastosowanie medyczne tych związków oraz sposób ich otrzymywania
DE602006011607D1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
JOP20220319B1 (ar) أزيلاستين كعلاج مضاد للفيروسات
MX2024000239A (es) Medicamentos que comprenden inhibidores de la glicosidasa.